Allogene Therapeutics, Inc. (ALLO) Stock AnalysisALLOAllogene Therapeutics, Inc.

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on three core programs: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID), and Renal Cell Carcinoma (RCC). It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL. Its pipeline also includes ALLO-316 and ALLO-329. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Allogene Therapeutics Inc (ALLO) is a good buy right now, trading at $2.02 with a recent RSI of 44.57, suggesting it is not overbought. The company has shown a 49.63% year-to-date increase, and analysts see potential price targets up to $11, indicating a strong upside. However, the main risk is the ongoing financial losses, with a reported net income loss of $42.68 million in Q2 2026, which could impact investor confidence.

4 analysts cover ALLO: 3 rate it Buy, 1 Hold and 0 Sell. The average price target is 8.50.